173 related articles for article (PubMed ID: 36897252)
21. Alternative complement pathway activation fragment Ba binds to C3b. Evidence that formation of the factor B-C3b complex involves two discrete points of contact.
Pryzdial EL; Isenman DE
J Biol Chem; 1987 Feb; 262(4):1519-25. PubMed ID: 3643213
[TBL] [Abstract][Full Text] [Related]
22. Insights into the Effects of Complement Factor H on the Assembly and Decay of the Alternative Pathway C3 Proconvertase and C3 Convertase.
Bettoni S; Bresin E; Remuzzi G; Noris M; Donadelli R
J Biol Chem; 2016 Apr; 291(15):8214-30. PubMed ID: 26903516
[TBL] [Abstract][Full Text] [Related]
23. Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.
Chen JY; Galwankar NS; Emch HN; Menon SS; Cortes C; Thurman JM; Merrill SA; Brodsky RA; Ferreira VP
Front Immunol; 2020; 11():1460. PubMed ID: 32793201
[TBL] [Abstract][Full Text] [Related]
24. Reconstitution of C5 convertase of the alternative complement pathway with isolated C3b dimer and factors B and D.
Hong K; Kinoshita T; Pramoonjago P; Kim YU; Seya T; Inoue K
J Immunol; 1991 Mar; 146(6):1868-73. PubMed ID: 2005382
[TBL] [Abstract][Full Text] [Related]
25. Eosinophil granule major basic protein regulates generation of classical and alternative-amplification pathway C3 convertases in vitro.
Weiler JM; Gleich GJ
J Immunol; 1988 Mar; 140(5):1605-10. PubMed ID: 3346544
[TBL] [Abstract][Full Text] [Related]
26. The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.
Risitano AM; Notaro R; Pascariello C; Sica M; del Vecchio L; Horvath CJ; Fridkis-Hareli M; Selleri C; Lindorfer MA; Taylor RP; Luzzatto L; Holers VM
Blood; 2012 Jun; 119(26):6307-16. PubMed ID: 22577173
[TBL] [Abstract][Full Text] [Related]
27. Preferential inactivation of the C5 convertase of the alternative complement pathway by factor I and membrane cofactor protein (MCP).
Seya T; Okada M; Matsumoto M; Hong KS; Kinoshita T; Atkinson JP
Mol Immunol; 1991 Oct; 28(10):1137-47. PubMed ID: 1833639
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the effects of activation of the alternative pathway of complement on erythrocytes with an isolated deficiency of decay accelerating factor.
Holguin MH; Martin CB; Bernshaw NJ; Parker CJ
J Immunol; 1992 Jan; 148(2):498-502. PubMed ID: 1370313
[TBL] [Abstract][Full Text] [Related]
29. Potentiation of factor H by heparin: a rate-limiting mechanism for inhibition of the alternative complement pathway.
Boackle RJ; Caughman GB; Vesely J; Medgyesi G; Fudenberg HH
Mol Immunol; 1983 Nov; 20(11):1157-64. PubMed ID: 6228720
[TBL] [Abstract][Full Text] [Related]
30. Stabilization of the amplification convertase of complement by monoclonal antibodies directed against human factor B.
Daha MR; Deelder AM; Van Es LA
J Immunol; 1984 May; 132(5):2538-42. PubMed ID: 6232321
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin.
Kievits F; Kijlstra A
Immunology; 1985 Mar; 54(3):449-56. PubMed ID: 3844370
[TBL] [Abstract][Full Text] [Related]
32. Trypanosoma lewisi: restriction of alternative complement pathway C3/C5 convertase activity.
Sturtevant JE; Balber AE
Exp Parasitol; 1987 Jun; 63(3):260-71. PubMed ID: 3556206
[TBL] [Abstract][Full Text] [Related]
33. Comparative study of in vitro inhibition of activation of the classical and alternative pathways of human complement by the magnesium and sodium salts of the anti-inflammatory peptide N-acetyl-aspartyl-glutamic acid (NAAGA).
Feuillard J; Maillet F; Goldschmidt P; Weiss L; Kazatchkine MD
Agents Actions; 1991 Mar; 32(3-4):343-6. PubMed ID: 1862751
[TBL] [Abstract][Full Text] [Related]
34. The MFHR1 Fusion Protein Is a Novel Synthetic Multitarget Complement Inhibitor with Therapeutic Potential.
Michelfelder S; Fischer F; Wäldin A; Hörle KV; Pohl M; Parsons J; Reski R; Decker EL; Zipfel PF; Skerka C; Häffner K
J Am Soc Nephrol; 2018 Apr; 29(4):1141-1153. PubMed ID: 29335241
[TBL] [Abstract][Full Text] [Related]
35. SARS-CoV-2-encoded ORF8 protein possesses complement inhibitory properties.
Kumar J; Dhyani S; Kumar P; Sharma NR; Ganguly S
J Biol Chem; 2023 Mar; 299(3):102930. PubMed ID: 36682494
[TBL] [Abstract][Full Text] [Related]
36. Characterization of alternative pathway inhibition by a serum derived, low molecular weight complement inhibitor.
Baker PJ; Parker CJ; Osofsky SG
Clin Exp Immunol; 1984 Jan; 55(1):166-76. PubMed ID: 6559107
[TBL] [Abstract][Full Text] [Related]
37. Site-specific activation of the alternative pathway of complement. Synthesis of a hybrid molecule consisting of antibody and cobra venom factor.
Parker CJ; White VF; Falk RJ
Complement; 1986; 3(4):223-35. PubMed ID: 3643079
[TBL] [Abstract][Full Text] [Related]
38. Glycoprotein C of herpes simplex virus 1 is an inhibitor of the complement cascade.
Fries LF; Friedman HM; Cohen GH; Eisenberg RJ; Hammer CH; Frank MM
J Immunol; 1986 Sep; 137(5):1636-41. PubMed ID: 3018078
[TBL] [Abstract][Full Text] [Related]
39. Small-molecule factor B inhibitor for the treatment of complement-mediated diseases.
Schubart A; Anderson K; Mainolfi N; Sellner H; Ehara T; Adams CM; Mac Sweeney A; Liao SM; Crowley M; Littlewood-Evans A; Sarret S; Wieczorek G; Perrot L; Dubost V; Flandre T; Zhang Y; Smith RJH; Risitano AM; Karki RG; Zhang C; Valeur E; Sirockin F; Gerhartz B; Erbel P; Hughes N; Smith TM; Cumin F; Argikar UA; Haraldsson B; Mogi M; Sedrani R; Wiesmann C; Jaffee B; Maibaum J; Flohr S; Harrison R; Eder J
Proc Natl Acad Sci U S A; 2019 Apr; 116(16):7926-7931. PubMed ID: 30926668
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of complement by covalent attachment of rosmarinic acid to activated C3b.
Sahu A; Rawal N; Pangburn MK
Biochem Pharmacol; 1999 Jun; 57(12):1439-46. PubMed ID: 10353266
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
